ICRM
ALXN

Insight Capital Research & Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Insight Capital Research & Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-21,298
Closed -$3.24M – 156
2014
Q1 		$3.24M Buy
+21,298
New +$3.39M 0.75% 59

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Insight Capital Research & Management's ALXN Position: Q2 2014 in Review

Insight Capital Research & Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2014, closing a stake of 21,298 shares — an estimated $3.24M sold.

Insight Capital Research & Management first reported a position in ALXN in Q1 2014 and held it in 1 quarter. The position peaked at $3.24M in Q1 2014. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • Insight Capital Research & Management reported no remaining Alexion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Insight Capital Research & Management sold 21,298 Alexion Pharmaceuticals shares in Q2 2014, an estimated $3.24M.
  • Insight Capital Research & Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Insight Capital Research & Management's Alexion Pharmaceuticals position peaked at $3.24M in Q1 2014.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Insight Capital Research & Management's 13F filing for Q2 2014, filed 13 Aug 2014.